News

Published on 20 Feb 2022 on Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead...


Article preview image

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.'s (NASDAQ: AGIO) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder.

NYSE.GKOS price evolution
NASDAQ.HALO price evolution
NASDAQ.HCAT price evolution
NASDAQ.ABCL price evolution
NYSE.EBS price evolution
NASDAQ.EDIT price evolution
NASDAQ.NEO price evolution
NASDAQ.NARI price evolution
NASDAQ.MMSI price evolution
NASDAQ.NTRA price evolution
NASDAQ.MGNX price evolution
NASDAQ.MASI price evolution
NASDAQ.PTC price evolution
NASDAQ.BMRN price evolution
NASDAQ.GH price evolution
NASDAQ.VIR price evolution
NASDAQ.PODD price evolution
NASDAQ.EXAS price evolution
NASDAQ.RETA price evolution
NASDAQ.NUVA price evolution
NASDAQ.IMGN price evolution
NASDAQ.SGMO price evolution
NYSE.NVTA price evolution
NYSE.BHC price evolution
NYSE.PEN price evolution
NASDAQ.PCRX price evolution
NASDAQ.IOVA price evolution
NASDAQ.PDSB price evolution
NASDAQ.AGIO price evolution
NASDAQ.CDNA price evolution
NASDAQ.CDXS price evolution
NASDAQ.OPK price evolution
NYSE.AVNS price evolution
NASDAQ.SNY price evolution
NASDAQ.ICUI price evolution
NASDAQ.LMAT price evolution
PAR.SAN price evolution
NYSE.GSK price evolution
LSE.GSK price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly ...

Benzinga via Yahoo Finance 8 Feb 2024

Great week for Invitae Corporation (NYSE:NVTA) institutional investors after losing 65% over the...

Key Insights Significantly high institutional ownership implies Invitae's stock price is sensitiv...

Simply Wall St. via Yahoo Finance 4 Sep 2023

Invitae Corporation (NYSE:NVTA) Stock's 27% Dive Might Signal An Opportunity But It Requires Some...

Invitae Corporation (NYSE:NVTA) shareholders that were waiting for something to happen have been ...

Simply Wall St. via Yahoo Finance 8 Jun 2023

Why Shares of Invitae Soared on Friday

Shares of Invitae Corporation (NYSE: NVTA) closed 11.57% higher on Friday after Cathie Wood, the ...

Motley Fool 17 Apr 2023

Invitae Corporation (NYSE:NVTA) is a favorite amongst institutional investors who own 68%

Key Insights Significantly high institutional ownership implies Invitae's stock price is sensitiv...

Simply Wall St. via Yahoo Finance 28 Mar 2023

Which Is the Better Buy: Vertex or Invitae?

Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions ...

Motley Fool 13 Feb 2023

13 Best Genomics Stocks To Buy Now

In this article, we discuss the 13 best genomics stocks to buy now. If you want to read about som...

Insider Monkey via Yahoo Finance 5 Dec 2022

Invitae: This Turnaround Could Be Painful (NYSE:NVTA)

Invitae Corporation (NYSE:NVTA) has one chance to leverage itself into profitability in the next ...

Seeking Alpha 15 Nov 2022

Why AirSculpt Technologies Shares Are Trading Lower By 20%; Here Are 31 Stocks Moving Premarket By...

Why AirSculpt Technologies Shares Are Trading Lower By 20%; Here Are 31 Stocks Moving Premarket

Investing.com 11 Nov 2022

Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates

Invitae (NVTA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estim...

Zacks via Yahoo Finance 9 Nov 2022